Eli Lilly said Friday that it will acquire Dermira, a small biotech developing drugs for chronic skin conditions, for $1.1 billion.

The centerpiece of the deal is the Dermira drug called lebrikizumab that aims to treat people suffering from moderate-to-severe atopic dermatitis, the most common form of eczema, a disease characterized by inflamed, itchy, and scaly skin.

advertisement

Phase 3 clinical trials of lebrikizumab in atopic dermatitis are underway. If successful, the drug could compete against Dupixent, which has grown into a commercial blockbuster for Regeneron Pharmaceuticals and Sanofi.

Get unlimited access to award-winning journalism and exclusive events.